172 related articles for article (PubMed ID: 20178321)
21. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
22. Solution structure of ectodomains of the insulin receptor family: the ectodomain of the type 1 insulin-like growth factor receptor displays asymmetry of ligand binding accompanied by limited conformational change.
Whitten AE; Smith BJ; Menting JG; Margetts MB; McKern NM; Lovrecz GO; Adams TE; Richards K; Bentley JD; Trewhella J; Ward CW; Lawrence MC
J Mol Biol; 2009 Dec; 394(5):878-92. PubMed ID: 19835884
[TBL] [Abstract][Full Text] [Related]
23. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
24. Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor.
Aware V; Gaikwad N; Chavan S; Manohar S; Bose J; Khanna S; B-Rao C; Dixit N; Singh KS; Damre A; Sharma R; Patil S; Roychowdhury A
Eur J Med Chem; 2015 Mar; 92():246-56. PubMed ID: 25559205
[TBL] [Abstract][Full Text] [Related]
25. Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.
Sampognaro AJ; Wittman MD; Carboni JM; Chang C; Greer AF; Hurlburt WW; Sack JS; Vyas DM
Bioorg Med Chem Lett; 2010 Sep; 20(17):5027-30. PubMed ID: 20675137
[TBL] [Abstract][Full Text] [Related]
26. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Chamberlain SD; Redman AM; Wilson JW; Deanda F; Shotwell JB; Gerding R; Lei H; Yang B; Stevens KL; Hassell AM; Shewchuk LM; Leesnitzer MA; Smith JL; Sabbatini P; Atkins C; Groy A; Rowand JL; Kumar R; Mook RA; Moorthy G; Patnaik S
Bioorg Med Chem Lett; 2009 Jan; 19(2):360-4. PubMed ID: 19071018
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells.
Momose I; Kunimoto S; Osono M; Ikeda D
Biochem Biophys Res Commun; 2009 Feb; 380(1):171-6. PubMed ID: 19166817
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel selective inhibitors for EGFR-T790M/L858R.
Bai F; Liu H; Tong L; Zhou W; Liu L; Zhao Z; Liu X; Jiang H; Wang X; Xie H; Li H
Bioorg Med Chem Lett; 2012 Feb; 22(3):1365-70. PubMed ID: 22227214
[TBL] [Abstract][Full Text] [Related]
29. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
[TBL] [Abstract][Full Text] [Related]
30. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
31. Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.
Velaparthi U; Liu P; Balasubramanian B; Carboni J; Attar R; Gottardis M; Li A; Greer A; Zoeckler M; Wittman MD; Vyas D
Bioorg Med Chem Lett; 2007 Jun; 17(11):3072-6. PubMed ID: 17398093
[TBL] [Abstract][Full Text] [Related]
32. Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Wilsbacher JL
ChemMedChem; 2007 Jan; 2(1):41-6. PubMed ID: 17089440
[No Abstract] [Full Text] [Related]
33. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.
Sekine Y; Furuya Y; Nishii M; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2008 Jul; 372(2):356-61. PubMed ID: 18489904
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells.
Bostedt KT; Schmid C; Ghirlanda-Keller C; Olie R; Winterhalter KH; Zapf J
Exp Cell Res; 2001 Dec; 271(2):368-77. PubMed ID: 11716549
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma.
Slomiany MG; Black LA; Kibbey MM; Tingler MA; Day TA; Rosenzweig SA
Cancer Lett; 2007 Apr; 248(2):269-79. PubMed ID: 16996205
[TBL] [Abstract][Full Text] [Related]
36. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.
Wittman MD; Balasubramanian B; Stoffan K; Velaparthi U; Liu P; Krishnanathan S; Carboni J; Li A; Greer A; Attar R; Gottardis M; Chang C; Jacobson B; Sun Y; Hansel S; Zoeckler M; Vyas DM
Bioorg Med Chem Lett; 2007 Feb; 17(4):974-7. PubMed ID: 17187980
[TBL] [Abstract][Full Text] [Related]
37. Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
Lesuisse D; Mauger J; Nemecek C; Maignan S; Boiziau J; Harlow G; Hittinger A; Ruf S; Strobel H; Nair A; Ritter K; Malleron JL; Dagallier A; El-Ahmad Y; Guilloteau JP; Guizani H; Bouchard H; Venot C
Bioorg Med Chem Lett; 2011 Apr; 21(8):2224-8. PubMed ID: 21441024
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
39. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
[TBL] [Abstract][Full Text] [Related]
40. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
